Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CCKAR | P32238 | 15/20 | 0.44 |
| ▸ | CCKBR | P32239 | 14/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8093477 | 0.75 | ALDH1A1 (0.61) | ALDH1A1CCKARCCKBRLMNATP53 | |
| SCHEMBL8093408 | 0.72 | ALDH1A1 (0.55) | ALDH1A1CCKARCCKBRLMNATP53 | |
| SCHEMBL7752992 | 0.71 | CCKAR (0.65) | ALDH1A1CCKARCCKBR | |
| SCHEMBL8081898 | 0.69 | ALDH1A1 (0.45) | ALDH1A1CCKARCCKBRLMNATP53 | |
| SCHEMBL7550570 | 0.69 | CCKAR (0.67) | ALDH1A1CCKARCCKBR | |
| SCHEMBL8807834 | 0.68 | CCKAR (0.58) | ALDH1A1CCKARCCKBR | |
| SCHEMBL8795883 | 0.67 | ALDH1A1 (0.58) | ALDH1A1CCKARCCKBR | |
| SCHEMBL17993540 | 0.66 | ALDH1A1 (0.65) | ALDH1A1CCKARCCKBRLMNATP53 | |
| SCHEMBL8795637 | 0.65 | ALDH1A1 (0.66) | ALDH1A1CCKARCCKBRLMNATP53 | |
| SCHEMBL8817635 | 0.65 | CCKAR (0.78) | ALDH1A1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | claimed |
| US-6096885-A | EXHIBIT AGONIST ACTIVITY FOR CCK-A RECEPTORS THEREBY ENABLING THEM TO MODULATE THE HORMONES GASTRIN AND CHOLECYSTOKININ IN MAMMALS. | GLAXO WELLCOME INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0785944-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011940-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | ALDH1A1 2992/4885CCKAR 1739/4885CCKBR 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.